{
  "drug_name": "Gatifloxacin",
  "tradename": "Tequin, Zymar",
  "usage_and_dosing": {
    "general": [
      "Gatifloxacin is a fluoroquinolone with efficacy against respiratory and enteric pathogens.",
      "Gatifloxacin was withdrawn from US and Canadian markets in 2006 due to drug-related hypo- and hyperglycemic reactions. See adverse effects. Still available in Europe and other regions.",
      "Ophthalmic solution (eyedrops) remains widely available."
    ],
    "adult_dose": {
      "usual_dose": "1 drop in affected eye as directed"
    },
    "pediatric_dose": {
      "dose_age_gt_28_days": "Safety and efficacy not established",
      "max_day": "-"
    }
  },
  "renal_adjustment": {
    "half_life_normal": "7-8",
    "half_life_esrd": "11-40",
    "dose_renal_function_normal": "400 mg po/IV q24h",
    "crcl_or_egfr": "CrCl >50: No dosage adjustment. CrCl 10-50: 400 mg, then 200 mg q24h. CrCl <10: 400 mg, then 200 mg q24h",
    "hemodialysis": "200 mg q24h (give dialysis day dose AD)",
    "capd": "200 mg q24h",
    "crrt": "400 mg, then 200 mg q24h",
    "sled": "No data"
  },
  "hepatic_adjustment": {
    "mild_impairment_child_pugh_a": "No dosage adjustment",
    "moderate_impairment_child_pugh_b": "No dosage adjustment",
    "severe_impairment_child_pugh_c": "No dosage adjustment"
  },
  "adverse_effects": [
    "Treatment stopped due to an adverse effect: 2.9%.",
    "Gatifloxacin-associated dysglycemia due to documented hypoglycemic and hyperglycemic reactions (NEJM 354:1352, 2006; Clin Infect Dis 49:402, 2009).",
    "For complete class-wide adverse effects see Fluoroquinolones, Overview and for QTc prolongation, see QTc Interval Prolongation.",
    "Any of the fluoroquinolones may exacerbate muscle weakness in persons with myasthenia gravis."
  ],
  "pregnancy_risk": {
    "fda_risk_category": "Avoid in pregnancy due to possible renal, cardiac, and CNS toxicity in the fetus. Consider use if no alternatives exist, and if benefit outweighs risk.",
    "lactation": "Short-term use safe, monitor infant for GI toxicity; avoid if possible.",
    "footnote": "Capital letter = Old FDA risk category; Text = New FDA risk category"
  },
  "antimicrobial_spectrum": {
    "preferred": [],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "24-hr AUC/MIC",
    "preparations": "Tab (200, 400 mg), 0.5% oph soln, Injection",
    "food_recommendation": "Tab ± food",
    "oral_absorption_percent": "96",
    "tmax_hr": "No data",
    "peak_serum_conc_ug_ml": "4.2-4.6 (400 mg po/IV q24h, SS)",
    "peak_urine_conc_ug_ml": "No data",
    "protein_binding_percent": "20",
    "volume_of_distribution_vd_l_kg_vss": "1.8 L/kg (Vss)",
    "avg_serum_half_life_hr": "7-8",
    "elimination": "Renal",
    "bile_penetration_percent": "No data",
    "csf_blood_percent": "36",
    "therapeutic_levels_in_csf": "No data",
    "auc_ug_hr_ml": "35 (400 mg po/IV q24h, 0-24 hr)"
  },
  "major_drug_interactions": [
      {"drug": "Antacids (Al, Mg)", "effect": "↓ gatifloxacin", "management": "Separate administration by"},
      {"drug": "Antiarrhythmics (Class IA/III)", "effect": "↑ QT interval", "management": "Avoid co-administrati"},
      {"drug": "Insulin", "effect": "↑↓ blood glucose", "management": "Monitor"},
      {"drug": "Iron supplements", "effect": "↓ gatifloxacin", "management": "Separate administration by"},
      {"drug": "NSAIDS", "effect": "↑ risk of CNS stimulation/seizures", "management": "Monitor or avoid"},
      {"drug": "Oral hypoglycemics", "effect": "↑↓ blood glucose", "management": "Monitor"},
      {"drug": "Probenecid", "effect": "↑ gatifloxacin", "management": "Monitor or avoid"},
      {"drug": "Sucralfate", "effect": "↓ gatifloxacin", "management": "Separate administration by"},
      {"drug": "Zinc", "effect": "↓ gatifloxacin", "management": "Separate administration by"}
  ]
}
